Janus Henderson Group’s Terns Pharmaceuticals TERN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$77.5M Sell
1,470,057
-1,909,512
-57% -$78.4M 0.04% 329
2025
Q4
$136M Buy
+3,379,569
New +$78.1M 0.06% 233
2024
Q2
Sell
-2,003,263
Closed -$13.1M 2583
2024
Q1
$13.1M Buy
2,003,263
+578,500
+41% +$3.78M 0.01% 641
2023
Q4
$9.25M Buy
+1,424,763
New +$7.53M 0.01% 686

Other funds holding TERN

Janus Henderson Group's TERN Position: Q1 2026 in Review

Janus Henderson Group reduced its Terns Pharmaceuticals (TERN) stake by 57% in Q1 2026, selling an estimated $78.4M and leaving 1,470,057 shares worth $77.5M. The position accounts for 0.04% of the portfolio, ranked #329.

Janus Henderson Group first reported a position in TERN in Q4 2023 and has held it in 4 quarters since. The position peaked at $136M in Q4 2025. 317 funds tracked by Wall St. Rank hold TERN as of Q1 2026.

  • Janus Henderson Group held 1,470,057 shares of Terns Pharmaceuticals worth $77.5M as of Q1 2026.
  • Janus Henderson Group sold 1,909,512 Terns Pharmaceuticals shares in Q1 2026, an estimated $78.4M.
  • Terns Pharmaceuticals made up 0.04% of Janus Henderson Group's portfolio in Q1 2026, its #329 holding.
  • Janus Henderson Group first reported a position in Terns Pharmaceuticals in Q4 2023 and has held it in 4 quarters since.
  • Janus Henderson Group's Terns Pharmaceuticals position peaked at $136M in Q4 2025.
  • 317 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q1 2026.

Based on Janus Henderson Group's 13F filing for Q1 2026, filed 15 May 2026.